on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies at the HC Wainwright Global Investment Conference
DBV Technologies, a biopharmaceutical company specializing in food allergy treatments, will participate in the 27th annual HC Wainwright Global Investment Conference. CEO Daniel Tassé will speak at a fireside chat on September 9, 2025, in New York City.
The company is offering a live webcast of this event, accessible via its website, which will be visible for 90 days. DBV Technologies is primarily working on the VIASKIN® patch, an innovative technology for treating allergies using epicutaneous immunotherapy.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news